Diffusion Pharmaceuticals Inc. (DFFN) financial statements (2021 and earlier)

Company profile

Business Address 2020 AVON COURT
CHARLOTTESVILLE, VA 22902
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments19148921222
Cash and cash equivalents19148921222
Other undisclosed current assets0011002
Total current assets:191591021224
Noncurrent Assets
Operating lease, right-of-use asset00
Property, plant and equipment0000000
Long-term investments and receivables     0 
Long-term investments     0 
Intangible assets, net (including goodwill)9991616719
Goodwill   77112
Intangible assets, net (excluding goodwill)9999966
Other noncurrent assets00000  
Total noncurrent assets:9991616819
TOTAL ASSETS:28241826172043
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2212313
Accounts payable1101200
Accrued liabilities2012112
Employee-related liabilities      1
Debt 0 12  
Other undisclosed current liabilities0     (1)
Total current liabilities:2213412
Noncurrent Liabilities
Long-term debt and lease obligation00  1  
Long-term debt, excluding current maturities    1  
Operating lease, liability00
Liabilities, other than long-term debt02223  
Deferred tax liabilities, net223  
Deferred income tax liabilities02
Other liabilities   00  
Other undisclosed noncurrent liabilities     22
Total noncurrent liabilities:0222422
Total liabilities:3435835
Stockholders' equity
Stockholders' equity attributable to parent2520162191638
Common stock0000000
Additional paid in capital131112968369116113
Accumulated deficit(106)(92)(80)(62)(60)(99)(75)
Total stockholders' equity:2520162191638
TOTAL LIABILITIES AND EQUITY:28241826172043

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Operating expenses(16)(12)(19)(11)(18)(24)(15)
Operating loss:(16)(12)(19)(11)(18)(24)(15)
Nonoperating income (expense)   (3) 0(3)
Other nonoperating income (expense)   (3) 00
Interest and debt expense  (0)(0)(0) (0)
Loss from continuing operations before equity method investments, income taxes:(16)(12)(19)(14)(18)(24)(17)
Other undisclosed income from continuing operations before income taxes00012  0
Loss from continuing operations before income taxes:(16)(11)(19)(2)(18)(24)(17)
Income tax expense (benefit)2(0)010 3
Net loss attributable to parent:(14)(12)(18)(1)(18)(24)(14)
Preferred stock dividends and other adjustments  (8)(1)   
Other undisclosed net loss available to common stockholders, basic(2)      
Net loss available to common stockholders, basic:(16)(12)(27)(3)(18)(24)(14)
Other undisclosed net loss available to common stockholders, diluted   (22)   
Net loss available to common stockholders, diluted:(16)(12)(27)(25)(18)(24)(14)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(14)(12)(18)(1)(18)(24)(14)
Comprehensive loss, net of tax, attributable to parent:(14)(12)(18)(1)(18)(24)(14)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: